ABSTRACT

Introduction

COVID-19-associated coagulopathy (CAC) is a well-recognized hematologic complication among patients with severe COVID-19 disease, where macro- and micro-thrombosis can lead to multiorgan injury and failure. Major societal guidelines that have published on the management of CAC are based on consensus of expert opinion, with the current evidence available. As a result of limited studies, there are many clinical scenarios that are yet to be addressed, with expert opinion varying on a number of important clinical issues regarding CAC management.

Methods

In this review, we utilize current societal guidelines to provide a framework for practitioners in managing their patients with CAC. We have also provided three clinical scenarios that implement important principles of anticoagulation in patients with COVID-19.

Conclusion

Overall, decisions should be made on acase by cases basis and based on the providers understanding of each patient’s medical history, clinical course and perceived risk.

中文翻译：

---

COVID-19 相关凝血病的具体细节：管理和治疗的要点

摘要

介绍

COVID-19 相关凝血病 (CAC) 是严重 COVID-19 疾病患者中公认的血液系统并发症，其中大血栓和小血栓可导致多器官损伤和衰竭。已发表的关于 CAC 管理的主要社会指南是基于专家意见的共识，并具有现有的证据。由于研究有限，有许多临床情况有待解决，专家对有关 CAC 管理的许多重要临床问题的意见各不相同。

方法

在这篇综述中，我们利用当前的社会指南为从业者管理 CAC 患者提供了一个框架。我们还提供了三种在 COVID-19 患者中实施抗凝重要原则的临床方案。

结论

总体而言，应根据具体情况并根据提供者对每位患者的病史、临床过程和感知风险的理解做出决定。